Proactive Investors - Run By Investors For Investors

Tavistock Investments: "extremely fussy" acquisition strategy driving performance

Brian Raven, group chief executive at Tavistock Investments PLC (LON:TAVI), talks to Proactive Investors about the group's performance over the past financial year, with progress registered by every subsidiary business as they became more profitable.

Raven says the group's "extremely fussy" acquisition strategy is an endorsement of its ability to "pick winners rather than losers" after acquisitions boosted the group's second half performance.

Raven says recent acquisition Abacus is a "well-run" business providing lots of synergies. He expects increased profits from Abacus during the current financial year which will also help group performance.

He says the company is "significantly undervalued" compared to peers. His long-term growth plans include building the asset management business Tavistock Wealth and move the funds under management "north of a billion" very quickly and targets £5 billion under influence by the end of next year.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full TAVI profile View Profile

Tavistock Investments Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use